Extended aficamten treatment in symptomatic obstructive HCM produced early, sustained hemodynamic and clinical improvements with low rates of atrial fibrillation and LVEF <50%.
Does extended aficamten treatment improve hemodynamic and clinical responses and maintain safety in patients with symptomatic oHCM?
Extended aficamten treatment provides sustained clinical and hemodynamic benefits with a favorable safety profile in symptomatic oHCM.
Absolute Event Rate: 0% vs 0%
Extended aficamten treatment in patients with symptomatic oHCM yielded early and sustained hemodynamic and clinical responses with low incidences of new-onset atrial fibrillation and LVEF<50%.
“These are important results. The reason is not the fact that we only change the structure itself, the reason is that every single one of these structural changes, or every single one of these structural abnormalities at baseline has been associated or is associated with adverse outcomes on long-term follow-up. As such, the ability for a medication like aficamten to reverse remodel the ventricle in a favorable way, as well as the atrium, gives us clues that, longer term, we should expect to see improvement in patient outcomes, as well as improvement on how patients do in long term that the studies themselves might not be designed to measure.”
Tower‐Rader et al. (Wed,) reported a other. Extended aficamten treatment in symptomatic obstructive HCM produced early, sustained hemodynamic and clinical improvements with low rates of atrial fibrillation and LVEF <50%.